TY - JOUR
T1 - Glial fibrillary acidic protein as a brain injury biomarker in children undergoing extracorporeal membrane oxygenation
AU - Bembea, Melania M.
AU - Savage, William
AU - Strouse, John J.
AU - Schwartz, Jamie Mc Elrath
AU - Graham, Ernest
AU - Thompson, Carol B.
AU - Everett, Allen
N1 - Funding Information:
The project described was supported by Grants Number UL1 RR 025005 and 1KL2RR025006-01 from the National Center for Research Resources (NCRR) , a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at www.ncrr.nih.gov . Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp (M.M.B.). Dr. Savage acknowledges support from the Johns Hopkins Clinical Hematology Development Program 5K12HL087169, 5R01HL091759 ; the National Heart, Lung and Blood Institute Proteomics and Genomics Hands-on Workshop 5T15HL086386 ; and Basic and Translational Research Program in Sickle Cell Disease , 1U54HL090515 .
PY - 2011/9
Y1 - 2011/9
N2 - Objective: To determine whether, in children, plasma glial fibrillary acidic protein is associated with brain injury during extracorporeal membrane oxygenation and with mortality. Design: Prospective, observational study. Setting: Pediatric intensive care unit in an urban tertiary care academic center. Patients: Neonatal and pediatric patients on extracorporeal membrane oxygenation (n = 22). Interventions: Serial blood sampling for glial fibrillary acidic protein measurements. Measurements and Main Results: Prospective patients age 1 day to 18 yrs who required extracorporeal membrane oxygenation from April 2008 to August 2009 were studied. Glial fibrillary acidic protein was measured using an electrochemiluminescent immunoassay developed at Johns Hopkins. Control samples were collected from 99 healthy children (0.5-16 yrs) and 59 neonatal intensive care unit infants without neurologic injury. In controls, the median glial fibrillary acidic protein concentration was 0.055 ng/mL (interquartile range, 0-0.092 ng/mL) and the 95th percentile of glial fibrillary acidic protein was 0.436 ng/mL. In patients on extracorporeal membrane oxygenation, plasma glial fibrillary acidic protein was measured at 6, 12, and every 24 hrs after cannulation. We enrolled 22 children who underwent extracorporeal membrane oxygenation. Median age was 7 days (interquartile range, 2 days to 9 yrs), and primary extracorporeal membrane oxygenation indication was: cardiac failure, six of 22 (27.3%); respiratory failure, 12 of 22 (54.5%); extracorporeal cardiopulmonary resuscitation, three of 22 (13.6%); and sepsis, one of 22 (4.6%). Seven of 22 (32%) patients developed acute neurologic injury (intracranial hemorrhage, brain death, or cerebral edema diagnosed by imaging). Fifteen of 22 (68%) survived to hospital discharge. In the extracorporeal membrane oxygenation group, peak glial fibrillary acidic protein levels were higher in children with brain injury than those without (median, 5.9 vs. 0.09 ng/mL, p = .04) and in nonsurvivors compared with survivors to discharge (median, 5.9 vs. 0.09 ng/mL, p = .04). The odds ratio for brain injury for glial fibrillary acidic protein >0.436 ng/mL vs. normal was 11.5 (95% confidence interval, 1.3-98.3) and the odds ratio for mortality was 13.6 (95% confidence interval, 1.7-108.5). Conclusions: High glial fibrillary acidic protein during extracorporeal membrane oxygenation is significantly associated with acute brain injury and death. Brain injury biomarkers may aid in outcome prediction and neurologic monitoring of patients on extracorporeal membrane oxygenation to improve outcomes and benchmark new therapies.
AB - Objective: To determine whether, in children, plasma glial fibrillary acidic protein is associated with brain injury during extracorporeal membrane oxygenation and with mortality. Design: Prospective, observational study. Setting: Pediatric intensive care unit in an urban tertiary care academic center. Patients: Neonatal and pediatric patients on extracorporeal membrane oxygenation (n = 22). Interventions: Serial blood sampling for glial fibrillary acidic protein measurements. Measurements and Main Results: Prospective patients age 1 day to 18 yrs who required extracorporeal membrane oxygenation from April 2008 to August 2009 were studied. Glial fibrillary acidic protein was measured using an electrochemiluminescent immunoassay developed at Johns Hopkins. Control samples were collected from 99 healthy children (0.5-16 yrs) and 59 neonatal intensive care unit infants without neurologic injury. In controls, the median glial fibrillary acidic protein concentration was 0.055 ng/mL (interquartile range, 0-0.092 ng/mL) and the 95th percentile of glial fibrillary acidic protein was 0.436 ng/mL. In patients on extracorporeal membrane oxygenation, plasma glial fibrillary acidic protein was measured at 6, 12, and every 24 hrs after cannulation. We enrolled 22 children who underwent extracorporeal membrane oxygenation. Median age was 7 days (interquartile range, 2 days to 9 yrs), and primary extracorporeal membrane oxygenation indication was: cardiac failure, six of 22 (27.3%); respiratory failure, 12 of 22 (54.5%); extracorporeal cardiopulmonary resuscitation, three of 22 (13.6%); and sepsis, one of 22 (4.6%). Seven of 22 (32%) patients developed acute neurologic injury (intracranial hemorrhage, brain death, or cerebral edema diagnosed by imaging). Fifteen of 22 (68%) survived to hospital discharge. In the extracorporeal membrane oxygenation group, peak glial fibrillary acidic protein levels were higher in children with brain injury than those without (median, 5.9 vs. 0.09 ng/mL, p = .04) and in nonsurvivors compared with survivors to discharge (median, 5.9 vs. 0.09 ng/mL, p = .04). The odds ratio for brain injury for glial fibrillary acidic protein >0.436 ng/mL vs. normal was 11.5 (95% confidence interval, 1.3-98.3) and the odds ratio for mortality was 13.6 (95% confidence interval, 1.7-108.5). Conclusions: High glial fibrillary acidic protein during extracorporeal membrane oxygenation is significantly associated with acute brain injury and death. Brain injury biomarkers may aid in outcome prediction and neurologic monitoring of patients on extracorporeal membrane oxygenation to improve outcomes and benchmark new therapies.
KW - Biochemical marker
KW - ECMO
KW - Extracorporeal membrane oxygenation
KW - GFAP
KW - Glial fibrillary acidic protein
KW - Intracranial hemorrhage
UR - http://www.scopus.com/inward/record.url?scp=80455168067&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80455168067&partnerID=8YFLogxK
U2 - 10.1097/PCC.0b013e3181fe3ec7
DO - 10.1097/PCC.0b013e3181fe3ec7
M3 - Article
C2 - 21057367
AN - SCOPUS:80455168067
SN - 1529-7535
VL - 12
SP - 572
EP - 579
JO - Pediatric Critical Care Medicine
JF - Pediatric Critical Care Medicine
IS - 5
ER -